Alnylam Pharmaceuticals (GB:0HD2)

Alnylam Pharma (0HD2) Share Price & Analysis


0HD2 Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$125.38 - $241.06
Previous Close$185.63
Average Volume (3M)357.00
Market Cap
Enterprise Value$22.47B
Total Cash (Recent Filing)$2.07B
Total Debt (Recent Filing)$1.32B
Price to Earnings (P/E)N/A
Aug 01, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
Shares Outstanding124,525,737
10 Day Avg. Volume45
30 Day Avg. Volume357
Standard Deviation0.15
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)58.45
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue15.96
Enterprise Value/Gross Profit12.69
Enterprise Value/Ebitda-37.64
Price Target Upside35.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16




What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest share price was $125.38 and its highest was $241.06 in the past 12 months.
    What is Alnylam Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Alnylam Pharmaceuticals’s upcoming earnings report date?
    Alnylam Pharmaceuticals’s upcoming earnings report date is Aug 01, 2023 which is in 60 days.
      How were Alnylam Pharmaceuticals’s earnings last quarter?
      Alnylam Pharmaceuticals released its earnings results on May 04, 2023. The company reported -$1.4 earnings per share for the quarter, beating the consensus estimate of -$1.67 by $0.27.
        Is Alnylam Pharmaceuticals overvalued?
        According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Alnylam Pharmaceuticals pay dividends?
          Alnylam Pharmaceuticals does not currently pay dividends.
          What is Alnylam Pharmaceuticals’s EPS estimate?
          Alnylam Pharmaceuticals’s EPS estimate is -$1.51.
            How many shares outstanding does Alnylam Pharmaceuticals have?
            Currently, no data Available
            What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
            Alnylam Pharmaceuticals reported an EPS of -$1.4 in its last earnings report, beating expectations of -$1.67. Following the earnings report the stock price went up 2.756%.
              Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
              Among the largest hedge funds holding Alnylam Pharmaceuticals’s share is Dodge & Cox. It holds Alnylam Pharmaceuticals’s shares valued at 780M.


                Alnylam Pharma Stock Smart Score

                The Alnylam Pharma Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                Learn more about TipRanks Smart Score

                Company Description

                Alnylam Pharmaceuticals

                Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Alnylam Pharma
                Sarepta Therapeutics
                Bluebird Bio
                Vertex Pharmaceuticals
                Ionis Pharmaceuticals

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis